Additive effects of leptin and topiramate in reducing fat deposition in lean and obese ob/ob mice.
The objective of the present study was to investigate the effects of the antiepileptic drug topiramate (TPM) on components of energy balance in lean and obese (ob/ob) mice in the presence or absence of leptin. Lean and ob/ob mice infused with either leptin or phosphate-buffered saline were treated with TPM for 7 days. TPM was mixed into the diet and administered at a dose of 60 mg/kg/day, whereas leptin was infused at the rate of 100 microg/kg/day using osmotic minipumps, which were subcutaneously implanted in the interscapular region. Food intake and body weight were monitored throughout the study. Body composition was measured prior to and following treatment with TPM and leptin, using dual-energy X-ray absorptiometry (DEXA). Glucose (glucose oxidase method) and insulin (radioimmunoassay) were also determined. TPM and leptin significantly reduced body weight gain, food intake and body fat gain in obese mice. The effects of TPM and leptin on fat gain were also statistically significant in lean animals. There was no interaction of TPM and leptin on the energy balance variables, the effects of the two substances being additive instead. Leptin abrogated hyperinsulinemia in obese mutants whereas TPM did not alter insulin levels in either lean or obese mice. The combination of leptin and TPM led to the normalization of glucose levels in obese mice. Our study demonstrates an effect of TPM in leptin-deficient animals, which suggests that TPM does not require the presence of leptin to exert its effect. They also show that the effects of leptin and TPM can be additive. The treatment with leptin in ob/ob mice neither accentuated nor blunted the effect of TPM on energy balance.
Lalonde
Josée
J
D.B. Brown Obesity Research Chair and Research Center of Laval Hospital, Laval University, Québec, PQ, Canada G1K 7P4.
Samson
Pierre
P
Poulin
Sébastien
S
Deshaies
Yves
Y
Richard
Denis
D
D000273:Adipose Tissue / Q000187:drug effects*; D000818:Animals; D019440:Anti-Obesity Agents / Q000008:administration & dosage*; D000927:Anticonvulsants / Q000008:administration & dosage; D001069:Appetite Regulation / Q000187:drug effects; D001823:Body Composition / Q000187:drug effects*; D001835:Body Weight / Q000187:drug effects; D004347:Drug Interactions; D004357:Drug Synergism; D004734:Energy Metabolism / Q000187:drug effects*; D005260:Female; D005632:Fructose / Q000008:administration & dosage* / Q000031:analogs & derivatives*; D015918:Infusion Pumps, Implantable; D007328:Insulin / Q000097:blood; D020738:Leptin / Q000008:administration & dosage / Q000502:physiology*; D051379:Mice; D008810:Mice, Inbred C57BL; D008820:Mice, Obese; D009765:Obesity / Q000378:metabolism; D000077236:Topiramate
D019440:Anti-Obesity Agents; D000927:Anticonvulsants; D007328:Insulin; D020738:Leptin; D000077236:Topiramate; D005632:Fructose